| Business Summary | | Endo
Pharmaceuticals
Holdings
Inc.
(Endo),
through
its
wholly
owned
subsidiaries,
Endo
Pharmaceuticals
Inc.
and
Endo
Inc.,
is
engaged
in
the
research,
development,
sales
and
marketing
of
branded
and
generic
prescription
pharmaceuticals
used
primarily
for
the
treatment
and
management
of
pain.
Endo
markets
branded
pharmaceutical
products
to
doctors,
drug
wholesalers
and
other
healthcare
professionals.
Endo
markets
its
generics
through
sales
and
marketing
activities
as
well
as
customer
service
activities
directly
with
wholesale
drug
distributors
and
chain
and
independent
retail
pharmacists.
Endo's
portfolio
of
branded
products
includes
recognized
brand
names
such
as
Percocet,
Percodan,
Zydone
and
Lidoderm.
Endo's
portfolio
of
generic
products
includes
products
for
various
indications,
most
of
which
are
focused
on
pain
management. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ENDP
is
engaged
in
the
research,
development,
sales
and
marketing
of
branded
and
generic
prescription
pharmaceuticals
used
for
the
treatment
and
management
of
pain.
For
the
six
months
ended
6/30/01,
net
sales
increased
56%
to
$107.2
million.
Net
loss
decreased
32%
to
$11.5
million.
Net
sales
reflect
an
increase
in
sales
of
several
new
products.
Net
loss
reflects
the
absence
of
a
$22
million
separation
benefits
charge
and
a
higher
gross
profit
due
to
a
change
in
product
mix. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Lyle, 57 Chairman | -- | Carol Ammon, 50 Pres,
CEO, Director | $336K | Mariann MacDonald, 53 Exec.
VP, Operations | 311K | Jeffrey Black, 36 Sr.
VP, CFO, Treasurer | 262K | Peter Lankau, 48 Sr.
VP, U.S. Bus. | 308K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|